Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30426333 | 1.00 | GLA (0.50) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL27986680 | 0.83 | GLA (0.47) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL2154019 | 0.82 | GLA (0.53) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL2153847 | 0.82 | HRH3 (0.59) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL5090668 | 0.80 | GLA (0.51) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL3063453 | 0.78 | ENPP2 (0.53) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL14249396 | 0.78 | PTPN1 (0.43) | GLAFFAR1 | |
| SCHEMBL8348137 | 0.78 | GLA (0.50) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL7053510 | 0.78 | GLA (0.50) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL126484 | 0.78 | GLA (0.50) | GLACYP19A1CYP11B1CYP11B2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105492433-B | 6- (5-hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as PHD inhibitors | 武田药品工业株式会社 | 2018-11-23 | — | — | CN | claimed |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | NXERA PHARMA UK LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2024-03-21 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| CN-112062670-B | Fluorination reagent and deoxidization fluorination method | 三明市海斯福化工有限责任公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| CN-114105722-A | Method for preparing organic fluorine compound | 浙江工业大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-101945853-A | Selective androgen receptor modulators (sarms) and uses thereof | LIGAND PHARM INC | 2011-01-12 | — | — | CN | disclosed |
| EP-1465880-B1 | 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE | IPSEN PHARMA (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | GLA 4179/4885CYP19A1 3133/4885CYP11B1 1312/4885 |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | GLA 4179/4885CYP19A1 3133/4885CYP11B1 1312/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | GLA 30/4885CYP19A1 1756/4885CYP11B1 1702/4885 |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | GLA 1064/4885CYP19A1 4664/4885CYP11B1 4352/4885 |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM6, GRM2 | GLA 4426/4885CYP19A1 3135/4885CYP11B1 1506/4885 |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | GLA 4426/4885CYP19A1 3135/4885CYP11B1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.